Breaking News
March 22, 2018 - Menopausal hormone therapy taken soon after menopause may benefit the brain
March 22, 2018 - Booze Boosts Your Heart Rate
March 22, 2018 - Skeptical Cardiologist: Classifying Heart Failure
March 22, 2018 - Instead of nagging your spouse to lose weight, try going on a diet yourself
March 22, 2018 - Study uncovers new genetic cause of posterior polymorphous corneal dystrophy
March 22, 2018 - ENDO: Big Breakfast May Help in Diabetics
March 22, 2018 - I’m not overweight, so why do I need to eat healthy foods?
March 22, 2018 - UCLA-led study suggests unexpected reason for reduction in cardiovascular health disparities
March 22, 2018 - Study suggests detailed neuropsychological assessment for brief cardiac arrest survivors
March 22, 2018 - Anticoagulant drugs found safe to use in patients undergoing surgery for irregular heartbeat
March 22, 2018 - SP Industries appoints Brian Larkin as new President and CEO
March 22, 2018 - GTx Announced New Data Demonstrating Enobosarm’s Potential to Treat Stress Urinary Incontinence
March 22, 2018 - Higher Risk of Brain Deficits in Older Alcoholics
March 22, 2018 - Top US health official resigns in conflict of interest
March 22, 2018 - Study shows benefits of hair loss drug in improving cognitive function and vascular health
March 22, 2018 - Researchers explain link between 2 key Alzheimer’s proteins
March 22, 2018 - Patients on replacement therapy with thyroid hormone may have more comorbidities
March 22, 2018 - Higher online patient ratings linked to urologists who saw fewer Medicare patients
March 22, 2018 - FDA Approves Ilumya (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis
March 22, 2018 - Beer Raises Heart Rate; KardiaBand Hyperkalemia Test; CHD Clinics
March 22, 2018 - A retinal implant that is more effective against blindness
March 22, 2018 - New system based on artificial intelligence provides reliable detection of breast cancer
March 22, 2018 - Research offers new understanding about cause of Parkinson’s disease
March 22, 2018 - HORIBA’s Microsemi CRP analyzer improves quality of care in emergency pediatric units, study shows
March 22, 2018 - Neuroscientists move closer to developing tools for deciphering brain function
March 22, 2018 - New test methods with less fear
March 22, 2018 - Range of Vaginal Dryness Products Can Help Postmenopausal Women: Study
March 22, 2018 - Higher Dose Tx Deemed Safe in Pulmonary TB
March 22, 2018 - Discovery of new ALS gene points to cytoskeleton as potential target for drug development
March 22, 2018 - Diet soda associated with higher odds of diabetic retinopathy
March 22, 2018 - LSD reduces ‘sense of self’
March 22, 2018 - Vitamin D deficiency linked to metabolic syndrome in postmenopausal women
March 22, 2018 - Changes in the intestines may be responsible for reversal of diabetes after bariatric surgery
March 22, 2018 - iPads and Cancer; Clot Retrieval and Stroke: It’s PodMed Double T!
March 22, 2018 - Premature births linked to changes in mother’s bacteria
March 22, 2018 - Brain SPECT scans predict treatment outcomes in patients with depression
March 21, 2018 - Researchers succeed in integrating artificial organelles into cells of living organism
March 21, 2018 - Researchers discover ‘missing mutation’ in severe infant epilepsy
March 21, 2018 - Researchers develop statistics-based computational scheme to zoom in on brain function
March 21, 2018 - Verge joins Genomics England’s Discovery Forum industry partnership
March 21, 2018 - Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial
March 21, 2018 - Congenital Cardiac Cath Tx Often Strays from Guidelines
March 21, 2018 - Marked increase in cardiovascular risk factors in women after preeclampsia
March 21, 2018 - New app may help predict, track manic and depressive episodes in bipolar patients
March 21, 2018 - Discovery of genes could lead to development of novel therapies for EBV-related cancers
March 21, 2018 - High-fat, high-cholesterol diet depletes ranks of artery-protecting immune cells
March 21, 2018 - Research misconduct allegations shadow likely CDC appointee
March 21, 2018 - Most Breast Ca Patients Fail to Get Genetic Counseling
March 21, 2018 - Lopsided ear function can lead to lopsided brain development
March 21, 2018 - Acupuncture helps manage menopausal symptoms, review finds
March 21, 2018 - Motor skill training may contribute to reading skills in obese children
March 21, 2018 - Poor dental health may be related to increased diabetes risk
March 21, 2018 - Chronic opioid users at increased risk of complications after spinal fusion surgery
March 21, 2018 - Study uncovers potential therapeutic target against large family of parasites
March 21, 2018 - NSAID use linked to increased risk of atrial fibrillation
March 21, 2018 - Scientists develop brain “stethoscope” that can detect silent seizures
March 21, 2018 - New method predicts effects of global warming on disease
March 21, 2018 - Insurance Company Hurdles Burden Doctors, May Harm Patients
March 21, 2018 - Renal Transplant from HCV-Positive Donors Feasible
March 21, 2018 - Myelodysplastic syndrome: MedlinePlus Medical Encyclopedia
March 21, 2018 - Research reveals brain mechanism involved in language learning
March 21, 2018 - Many parents still hesitate to try early peanut introduction, survey finds
March 21, 2018 - Audiologist urges tinnitus sufferers facing ‘revolving door healthcare’ to seek support
March 21, 2018 - Study reveals impact of prostate cancer on wives and partners of sufferers
March 21, 2018 - ‘Almost a Miracle Drug’: What We Heard This Week
March 21, 2018 - Study shows NIH spent >$100 billion on basic science for new medicines
March 21, 2018 - Columbia researchers identify nerve cells that drive fruit fly’s escape behavior
March 21, 2018 - Sartorius Stedim Biotech selected by ABL Europe to supply single-use process technologies
March 21, 2018 - Increase in coffee consumption may help battle against colon cancer
March 21, 2018 - Hydrogel may accelerate healing of diabetic ulcers
March 21, 2018 - Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
March 21, 2018 - DePuy Synthes introduces ACTIS Total Hip System for improving initial implant stability
March 21, 2018 - ‘Oh, It Was Nothing’
March 21, 2018 - Herbal drug kratom linked to salmonella illnesses, CDC says
March 21, 2018 - New optical point-of-care device could enhance screening for thyroid nodules
March 21, 2018 - FDA Expands Approval of Adcetris (brentuximab vedotin) for First-Line Treatment of Stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy
March 21, 2018 - Eosinophilic Esophagitis: Late Manifestation of Allergic March
March 21, 2018 - Signaling pathway involving the Golgi apparatus identified in cells with Huntington’s disease
March 21, 2018 - Quintupling inhaled steroid doses may not benefit children with asthma
March 21, 2018 - Study shows clear connection between cardiovascular fitness in middle age and dementia risk
CHEST: Novel Agent Boosts Quality of Life in COPD

CHEST: Novel Agent Boosts Quality of Life in COPD

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • Revefenacin, an investigational long-acting nebulized drug for chronic obstructive pulmonary disease (COPD), improved patient quality of life in two pivotal phase III placebo-controlled studies.
  • Note that revefenacin, if FDA-approved, would be the first once daily, long-acting muscarinic antagonist (LAMA) indicated for patients with COPD.

TORONTO — An investigational long-acting drug for chronic obstructive pulmonary disease (COPD), delivered by nebulizer, improved patient quality of life in two pivotal studies, researchers said here.

In a pooled analysis of the placebo-controlled phase III trials 0126 and 0127, patients reported marked improvement on two scales, the St George’s Respiratory Questionnaire (SGRQ) and COPD Assessment Test (CAT) with revefenacin treatment, according to James Donohue, MD, of the University of North Carolina in Chapel Hill, and colleagues.

On both scales, patients reported “clinically meaningful” responses to the drug in secondary analyses, Donohue reported at CHEST, the American College of Chest Physicians annual meeting.

If approved, revefenacin would be the first once daily, long-acting muscarinic antagonist (LAMA) indicated for patients with COPD, Donohue said. He told MedPage Today it would be an important addition to the armamentarium of therapy for patients who require a nebulized treatment.

“What’s unique is that it’s in a nebulizer and it’s 24 hours,” he noted.

The results of the study are “important,” commented CHEST session co-moderator Arthur Gelb, MD, of the University of California Los Angeles. “Hopefully, [the drug] will reach clinical utilization soon.”

Donohue said the FDA is expected to make a decision soon, although it’s unclear which of two tested doses will get the nod.

Gelb told MedPage Today that one advantage of revefenacin is that it would be the “only LAMA that would be inline,” which would make it more economical to use for patients admitted to hospital.

The two studies were identical, with 1,229 patients randomly assigned on a 1:1:1 basis to placebo, 88 μg of revefenacin, or 175 μg of the drug. The primary endpoints were efficacy and safety over a 12-week period, he said.

Patients in the study were well balanced across the arms in terms of demographics. About half were current smokers and a similar proportion reported a modified Medical Research Council dyspnea score of at least 2.

Patients had moderate to severe COPD with a high risk of exacerbations, with most having GOLD system scores of 2 or 3 on numerical scoring or B and C on the alphabetical scale. Participants were “very typical” of patients in a COPD trial, Donohue said.

He noted that investigators have earlier reported that the drug had beneficial effects on breathing, with “robust” and statistically significant improvements, compared with placebo, in one-second forced expiratory volume (FEV1).

Also, the rate of adverse events in the three arms was similar, with “no really clear-cut effect in [adverse events] of the higher dose.”

Aside from efficacy and safety, key secondary analyses included patient reported outcomes, at baseline and on day 85 of treatment, on the SGRQ and CAT. The researchers recorded total scores and proportion of responders.

The analysis showed that in the 0126 study, total SGRQ scores were similar for both doses, with a significant drop of about 4 points from baseline, compared with a slight but non-significant increase among those on placebo. The greatest improvement was seen on the symptom subscale.

In the 0127 study, outcomes were much the same, but a greater than expected placebo response meant that the change with the lower dose of revefenacin did not reach statistical significance.

Over both studies, patients taking the drug were about 50% more likely to reach the 4-point improvement threshold than those on placebo, with an odds ratio of 1.56 for 88-μg dose and an OR 1.53 for the 175-μg dose.

In study 0126, both doses significantly improved total scores on the CAT, but again owing to the unexpected placebo response, only the 175-μg dose had significantly better scores in the 0127 study.

In 0126, both doses were significantly associated with a clinically meaningful CAT response, but in 0127, only the higher dose was significantly better than placebo.

Taken together, the studies demonstrated “improvements in the health status” of people using revefenacin, according to Donohue.

The study was supported by Theravance Biopharma. Several co-authors are company employees.

Donohue disclosed relevant relationships with Theravance Biopharma, Mylan, and Sunovion.

Gelb disclosed no relevant relationships with industry.


Tagged with:

About author

Related Articles